MICAI: Multimodal Imaging in Vitreo-retinal Surgery and Macular Dystrophies

Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05747144
Collaborator
(none)
100
1
36
2.8

Study Details

Study Description

Brief Summary

The aim of the study is to identify morphological and functional biomarkers of post-operative recovery after vitreoretinal surgery, using decisional support systems (DSS), based on multimodal big-data analysis by means of machine learning techniques in daily clinical practice

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Biometry
  • Diagnostic Test: Retinography (Color) + Autofluorescence (AF)
  • Diagnostic Test: OCT B-scan and OCT angiography (OCTA)
  • Diagnostic Test: Microperimetry
  • Diagnostic Test: Electrophysiological exams

Detailed Description

The aim of the study is to identify morphological and functional biomarkers of post-operative recovery after vitreoretinal surgery. Identifying the biomarkers and assessing the predictivity of recovery will make it possible to highlight the categories of patients who can benefit most from surgical treatment, and to target the patient more precisely for personalised medicine and surgery. The introduction of new decisional support systems (DSS), based on multimodal big-data analysis through machine learning techniques in daily clinical practice, is providing new useful information in patient assessment for personalised surgery.

Study Design

Study Type:
Observational
Actual Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Multimodal Imaging in Vitreo-retinal Surgery and Macular Dystrophies: Biomarkers of Morpho-Functional Recovery by Artificial Intelligence
Actual Study Start Date :
Jan 15, 2021
Anticipated Primary Completion Date :
Jan 15, 2024
Anticipated Study Completion Date :
Jan 16, 2024

Arms and Interventions

Arm Intervention/Treatment
Macular hole

Patients affected by macular hole.

Diagnostic Test: Biometry
Biometric measurements performed with IOL Master, if executable Contact or immersion echobiometry if IOL Master cannot be performed

Diagnostic Test: Retinography (Color) + Autofluorescence (AF)
Colour + AF: EIDON, if available (60° not modulable) Colour: COBRA (60° non-modifiable) AF: Spectralis-Heidelberg (choose 55°) Other if available (choose posterior pole examination between 50-60°)

Diagnostic Test: OCT B-scan and OCT angiography (OCTA)
OCT B-scan: 2 scans (6 mm) 1 cross line OCTA: 3x3 mm + 6x6 mm centred on the fovea 4.5 mm centred on the optic nerve

Diagnostic Test: Microperimetry
1) fixation pattern 2) retinal sensitivity map

Diagnostic Test: Electrophysiological exams
Layer-by-layer assessment of the retina using focal ERG and pattern ERG according to standardised and published methods , For patients with visus < 3/10 and unstable fixation a protocol based on component analysis of the photopic ERG from diffuse flash will be used.

Epiretinal membranes

Patients affected by epiretinal membrane.

Diagnostic Test: Biometry
Biometric measurements performed with IOL Master, if executable Contact or immersion echobiometry if IOL Master cannot be performed

Diagnostic Test: Retinography (Color) + Autofluorescence (AF)
Colour + AF: EIDON, if available (60° not modulable) Colour: COBRA (60° non-modifiable) AF: Spectralis-Heidelberg (choose 55°) Other if available (choose posterior pole examination between 50-60°)

Diagnostic Test: OCT B-scan and OCT angiography (OCTA)
OCT B-scan: 2 scans (6 mm) 1 cross line OCTA: 3x3 mm + 6x6 mm centred on the fovea 4.5 mm centred on the optic nerve

Diagnostic Test: Microperimetry
1) fixation pattern 2) retinal sensitivity map

Diagnostic Test: Electrophysiological exams
Layer-by-layer assessment of the retina using focal ERG and pattern ERG according to standardised and published methods , For patients with visus < 3/10 and unstable fixation a protocol based on component analysis of the photopic ERG from diffuse flash will be used.

Retinal detachment

Patients affected by retinal detachment.

Diagnostic Test: Biometry
Biometric measurements performed with IOL Master, if executable Contact or immersion echobiometry if IOL Master cannot be performed

Diagnostic Test: Retinography (Color) + Autofluorescence (AF)
Colour + AF: EIDON, if available (60° not modulable) Colour: COBRA (60° non-modifiable) AF: Spectralis-Heidelberg (choose 55°) Other if available (choose posterior pole examination between 50-60°)

Diagnostic Test: OCT B-scan and OCT angiography (OCTA)
OCT B-scan: 2 scans (6 mm) 1 cross line OCTA: 3x3 mm + 6x6 mm centred on the fovea 4.5 mm centred on the optic nerve

Diagnostic Test: Microperimetry
1) fixation pattern 2) retinal sensitivity map

Diagnostic Test: Electrophysiological exams
Layer-by-layer assessment of the retina using focal ERG and pattern ERG according to standardised and published methods , For patients with visus < 3/10 and unstable fixation a protocol based on component analysis of the photopic ERG from diffuse flash will be used.

Macular dystrophies

Patients affected by macular dystrophies.

Diagnostic Test: Biometry
Biometric measurements performed with IOL Master, if executable Contact or immersion echobiometry if IOL Master cannot be performed

Diagnostic Test: Retinography (Color) + Autofluorescence (AF)
Colour + AF: EIDON, if available (60° not modulable) Colour: COBRA (60° non-modifiable) AF: Spectralis-Heidelberg (choose 55°) Other if available (choose posterior pole examination between 50-60°)

Diagnostic Test: OCT B-scan and OCT angiography (OCTA)
OCT B-scan: 2 scans (6 mm) 1 cross line OCTA: 3x3 mm + 6x6 mm centred on the fovea 4.5 mm centred on the optic nerve

Diagnostic Test: Microperimetry
1) fixation pattern 2) retinal sensitivity map

Diagnostic Test: Electrophysiological exams
Layer-by-layer assessment of the retina using focal ERG and pattern ERG according to standardised and published methods , For patients with visus < 3/10 and unstable fixation a protocol based on component analysis of the photopic ERG from diffuse flash will be used.

Outcome Measures

Primary Outcome Measures

  1. Predictivity of morphological-functional radiomic data [3 years]

    Predictivity of morphological-functional radiomic data to establish the grade of recovery in the post-operative period by means of an artificial intelligence (AI) machine learning model.

Secondary Outcome Measures

  1. Identify predictive differences according to diagnosis [3 years]

    Subdivision into subgroups in order to identify predictive differences according to diagnosis

  2. Correlating with the age of patients [3 years]

    Identify predictive differences according to diagnosis and correlate them with the age of patients

  3. Correlate with age of onset of disease [3 years]

    Identify predictive differences according to diagnosis and correlate them with the age of onset of disease

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Months and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All patients to undergo vitreo-retinal surgery for:
  1. Macular hole

  2. Epiretinal membranes

  3. Retinal detachment

  4. Macular dystrophies (retinal pre-prosthesis)

Exclusion Criteria:
  • Patients under 18 years of age will be excluded; patients in whom morphological examinations cannot be performed due to poor cooperation or opacity of the dioptric media (e.g. corneal pathology). Quality of morphological images inadequate for post acquisition processing (<6/10).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Prof. Stanislao Rizzo Rome Italy 00168

Sponsors and Collaborators

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
RIZZO STANISLAO, Professor, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
ClinicalTrials.gov Identifier:
NCT05747144
Other Study ID Numbers:
  • 3680
First Posted:
Feb 28, 2023
Last Update Posted:
Feb 28, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by RIZZO STANISLAO, Professor, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 28, 2023